• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

    9.470 +0.620 (+7.01%)
    Streaming Delayed Price Updated: 12:39 PM EST, Feb 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 385,312
    Open 8.660
    Bid (Size) 9.460 (200)
    Ask (Size) 9.480 (300)
    Prev. Close 8.850
    Today's Range 8.660 - 9.520
    52wk Range 6.660 - 18.90
    Shares Outstanding 95,568,307
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗
    These two biotechs only have one marketable therapy each, but both have blockbuster potential. 
    Via The Motley Fool
    News headline image
    ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -17.6%
    -17.6%
    1 Month
    -9.4%
    -9.4%
    3 Month
    +29.4%
    +29.4%
    6 Month
    -32.5%
    -32.5%
    1 Year
    -19.5%
    -19.5%

    More News

    Read More
    News headline image
    EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 10, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Outlook For ARS Pharmaceuticals ↗
    Via Benzinga
    News headline image
    California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharma SPRY Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    ARS Pharmaceuticals Inc (NASDAQ:SPRY) Tops Q3 2025 Revenue Forecasts Amid Wider-Than-Expected Loss ↗
    Via Chartmill
    News headline image
    ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment ↗
    Via Benzinga
    News headline image
    neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharma Sales Jump 3,040% in Q2 ↗
    Via The Motley Fool
    News headline image
    ARS Pharmaceuticals Inc (NASDAQ:SPRY) Reports Mixed Q2 2025 Earnings with Revenue Beat but Investor Caution Persists ↗
    Via Chartmill
    News headline image
    ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is ARS Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, ARS Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does ARS Pharmaceuticals, Inc. - Common Stock trade on?
    ARS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock is SPRY on the Nasdaq Stock Market
    What is the current price of ARS Pharmaceuticals, Inc. - Common Stock?
    The current price of ARS Pharmaceuticals, Inc. - Common Stock is 9.470
    When was ARS Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of ARS Pharmaceuticals, Inc. - Common Stock was at 02/17/26 12:39 PM ET
    What is the market capitalization of ARS Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of ARS Pharmaceuticals, Inc. - Common Stock is 905.03M
    How many shares of ARS Pharmaceuticals, Inc. - Common Stock are outstanding?
    ARS Pharmaceuticals, Inc. - Common Stock has 905M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.